MEDNAX, INC.: insider trades · United States · SEC (Form 4)

About MEDNAX, INC.

MEDNAX, Inc. is a U.S.-listed healthcare company traded on the NYSE under the ticker MD, and its operating footprint is in the United States. The group is now more widely known by its Pediatrix Medical Group brand, reflecting a long strategic shift toward specialized physician services. Founded in 1979 as a single neonatology practice, the company expanded over time and later refocused its portfolio on higher-acuity hospital-based care. Its headquarters are in Sunrise, Florida, which underscores its operational base in the southeastern United States. The company’s business model is centered on physician-led medical services rather than pharmaceuticals or devices. MEDNAX works through affiliated physicians and clinicians in partnership with hospitals, health systems, and other care facilities. Its core service lines include neonatology, obstetrics, maternal-fetal medicine, and other pediatric and hospital-based subspecialty services. Public company materials describe a service set that includes neonatal intensive care units, newborn nurseries, maternal-fetal medicine, pediatric intensive care, pediatric hospitalist coverage, OB hospitalist services, hearing-screen services, and telehealth support for inpatient programs. This makes MEDNAX a provider of essential clinical infrastructure, with demand tied to hospital utilization and maternal/infant care needs rather than discretionary consumer spending. From a competitive standpoint, MEDNAX operates in a fragmented but highly specialized healthcare segment. Its differentiation comes from clinical expertise, hospital relationships, geographic breadth, physician recruitment, and operational execution. The company’s longstanding presence in neonatal and maternal care is a notable asset, because these specialties require deep medical capability, strong hospital integration, and reliable 24/7 coverage. The business is overwhelmingly domestic, with revenue and activity concentrated in the United States, which is an important consideration for investors evaluating reimbursement exposure, payer mix, and regulatory risk. Recent company disclosures indicate that MEDNAX has continued its strategic repositioning toward core hospital-based specialties. Quarterly updates in 2025 and early 2026 pointed to improving operational performance and a sharper focus on higher-acuity service lines. In parallel, SEC Form 4 insider transaction filings have remained relevant for investors tracking management alignment and insider activity. Overall, MEDNAX remains a specialized healthcare services platform with a defensive end-market profile, listed on the NYSE in the United States, and positioned around recurring demand for neonatal, obstetric, and pediatric physician coverage.